|Bid||5,123.45 x 100|
|Ask||0.00 x 100|
|Day's range||5,951.00 - 5,951.00|
|52-week range||4,766.00 - 8,700.00|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||23.86|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.
In the latest trading session, Biogen Inc. (BIIB) closed at $295.95, marking a -1.98% move from the previous day.
Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.